Get ahead with in-depth pharmaceutical competitive intelligence
Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.
To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.
What we offer
You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.
Build detailed competitive and market landscape analyses quickly, with access to global information on:
How it helps
We help you more accurately:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Real-time tracking and analysis of the drug development pipeline
Key benefits:
Biomedtracker, Scrip
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Scrip
Could Serum Institute or Bharat Biotech be the first company to have a COVID-19 vaccine for children under 12 years of age? While Pfizer and Moderna have begun pediatric trials for children 12 years and above, Serum plans to begin testing its indigenous vaccine and Bharat Biotech its Covaxin in children under 12
Topic Coronavirus
Scrip
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Topic Coronavirus
Citeline, Sitetrove, Trialtrove
Even one misstep in your clinical trials strategy or execution can cost your company millions. Save time and cost with the trusted source for global investigator and site intelligence and global pharmaceutical clinical trial intelligence by subscribing to Sitetrove and Trialtrove.
Topic Clinical Trials Coronavirus
Scrip
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things
Scrip
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism
Topic Coronavirus Vaccines
Scrip
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
Topic Coronavirus Vaccines
Scrip
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Topic Parkinson's Disease
Scrip
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Topic China Infectious Diseases Policy & Regulation Coronavirus
Scrip
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Scrip
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Topic Coronavirus
Scrip
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Topic Coronavirus Financing Innovation
Scrip
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Topic Obesity Clinical Trials
Scrip
On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.
Topic Influenza Virus
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Scrip
21 Jan 2021
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: